• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰高血糖素样肽-2对假饲刺激的人胃酸分泌的抑制作用。

Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.

作者信息

Wøjdemann M, Wettergren A, Hartmann B, Hilsted L, Holst J J

机构信息

Department of Surgery, Rigshospitalet, Copenhagen, Denmark.

出版信息

J Clin Endocrinol Metab. 1999 Jul;84(7):2513-7. doi: 10.1210/jcem.84.7.5840.

DOI:10.1210/jcem.84.7.5840
PMID:10404829
Abstract

Glucagon-like peptide (GLP)-2 is formed from proglucagon in the intestinal L cells and is secreted postprandially in parallel with the insulinotropic hormone GLP-1, the latter of which, in addition, acts to inhibit gastric secretion and motility by inhibiting central parasympathetic outflow. We now studied the effect of GLP-2 on gastric secretion stimulated by sham feeding to test the hypothesis that also GLP-2 acts as an enterogastrone. Eight healthy volunteers were studied twice on separate days. They were sham fed with and without GLP-2 infused iv at a rate of 0.8 pmol/kg x min. Gastric contents were aspirated continuously by a nasogastric tube for determination of acid secretion, volume, and osmolarity. Sham feeding increased gastric acid secretion nearly 5-fold. Infusion of GLP-2 reduced incremental acid secretion by 65+/-6%, compared with saline infusion (delta8.75+/-0.37 vs. delta3.04+/-0.47 mmol x 60 min; P<0.01). Plasma concentrations of GLP-2 rose from a basal mean of 3.3+/-0.9 to a mean of 115+/-8 pmol/L (range, 57-149 pmol/L) during infusion of GLP-2 and remained at basal level during saline infusion. Plasma concentrations of GLP-1, gastrin, cholecystokinin, and secretin remained low and unchanged on both study days. We conclude that GLP-2 is a powerful inhibitor of gastric acid secretion in man. Further investigations will show to what extent GLP-2 contributes to the inhibitory effects on gastric secretion exerted by hormones from the distal small intestine, under physiological circumstances.

摘要

胰高血糖素样肽(GLP)-2由肠道L细胞中的胰高血糖素原生成,在餐后与促胰岛素激素GLP-1一同分泌,此外,GLP-1还通过抑制中枢副交感神经传出神经来抑制胃酸分泌和胃动力。我们现在研究了GLP-2对假饲刺激的胃酸分泌的影响,以验证GLP-2也作为一种肠抑胃素的假说。8名健康志愿者在不同日期接受了两次研究。他们在静脉输注或不输注GLP-2(速率为0.8 pmol/kg×min)的情况下进行假饲。通过鼻胃管持续抽吸胃内容物,以测定胃酸分泌、容量和渗透压。假饲使胃酸分泌增加近5倍。与输注生理盐水相比,输注GLP-2使胃酸分泌增量减少65±6%(分别为8.75±0.37 mmol×60 min和3.04±0.47 mmol×60 min;P<0.01)。在输注GLP-2期间,血浆GLP-2浓度从基础平均值3.3±0.9升高至平均值115±8 pmol/L(范围为57 - 149 pmol/L),而在输注生理盐水期间保持在基础水平。在两个研究日,血浆GLP-1、胃泌素、胆囊收缩素和促胰液素浓度均保持较低且无变化。我们得出结论,GLP-2是人体胃酸分泌的强效抑制剂。进一步的研究将表明,在生理情况下,GLP-2在多大程度上对远端小肠激素对胃酸分泌的抑制作用有贡献。

相似文献

1
Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.胰高血糖素样肽-2对假饲刺激的人胃酸分泌的抑制作用。
J Clin Endocrinol Metab. 1999 Jul;84(7):2513-7. doi: 10.1210/jcem.84.7.5840.
2
Glucagon-like peptide-1-(7-36) amide and peptide YY mediate intraduodenal fat-induced inhibition of acid secretion in dogs.胰高血糖素样肽-1(7-36)酰胺和肽YY介导十二指肠内脂肪诱导的犬胃酸分泌抑制。
Endocrinology. 1998 Jan;139(1):189-94. doi: 10.1210/endo.139.1.5700.
3
Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man.胰高血糖素样肽-1 7-36酰胺和肽YY对人胃酸分泌具有相加抑制作用。
Scand J Gastroenterol. 1997 Jun;32(6):552-5. doi: 10.3109/00365529709025098.
4
Glucagon-like peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man.来自回肠黏膜L细胞的胰高血糖素样肽-1 7-36酰胺和肽YY是人体迷走神经诱导胃酸分泌的有效抑制剂。
Scand J Gastroenterol. 1994 Jun;29(6):501-5. doi: 10.3109/00365529409092462.
5
Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs.胰高血糖素样肽-2抑制猪中枢诱导的胃窦运动。
Scand J Gastroenterol. 1998 Aug;33(8):828-32. doi: 10.1080/00365529850171486.
6
Lack of effect of synthetic human gastric inhibitory polypeptide and glucagon-like peptide 1 [7-36 amide] infused at near-physiological concentrations on pentagastrin-stimulated gastric acid secretion in normal human subjects.在正常人类受试者中,以接近生理浓度输注合成人胃抑制多肽和胰高血糖素样肽1[7-36酰胺]对五肽胃泌素刺激的胃酸分泌无影响。
Digestion. 1992;52(3-4):214-21. doi: 10.1159/000200956.
7
Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.在外源性合成人胃抑制多肽和胰高血糖素样肽-1-(7-36)酰胺以接近生理促胰岛素激素和葡萄糖浓度输注时的相加促胰岛素作用。
J Clin Endocrinol Metab. 1993 Apr;76(4):912-7. doi: 10.1210/jcem.76.4.8473405.
8
GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans.
Dig Dis Sci. 1989 May;34(5):703-8. doi: 10.1007/BF01540341.
9
Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion.迷走神经在介导近端营养素诱导的胰高血糖素样肽-1分泌中的作用。
Endocrinology. 1999 Apr;140(4):1687-94. doi: 10.1210/endo.140.4.6643.
10
Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum.神经递质和胃肠激素对离体血管灌注大鼠回肠中胰高血糖素样肽-1-(7-36)酰胺、肽YY和神经降压素分泌的调节
Endocrinology. 1995 Nov;136(11):5182-8. doi: 10.1210/endo.136.11.7588257.

引用本文的文献

1
Gut Hormones and Inflammatory Bowel Disease.肠道激素与炎症性肠病
Biomolecules. 2025 Jul 14;15(7):1013. doi: 10.3390/biom15071013.
2
Computational Design of Potent and Selective d-Peptide Agonists of the Glucagon-like Peptide-2 Receptor.基于计算设计的胰高血糖素样肽-2 受体强效高选择性 d-肽激动剂。
J Med Chem. 2023 Aug 10;66(15):10342-10353. doi: 10.1021/acs.jmedchem.3c00464. Epub 2023 Jul 25.
3
RISING STARS: Endocrine regulation of metabolic homeostasis via the intestine and gut microbiome.崭露头角的新星:肠道和肠道微生物组通过内分泌调节代谢稳态。
J Endocrinol. 2023 Jul 11;258(2). doi: 10.1530/JOE-23-0019. Print 2023 Aug 1.
4
Effects of glepaglutide, a long-acting glucagon-like peptide-2 analog, on intestinal morphology and perfusion in patients with short bowel syndrome: Findings from a randomized phase 2 trial.胰高血糖素样肽-2 类似物 glepaglutide 对短肠综合征患者肠道形态和灌注的影响:一项随机 2 期试验的结果。
JPEN J Parenter Enteral Nutr. 2023 Jan;47(1):140-150. doi: 10.1002/jpen.2389. Epub 2022 May 31.
5
Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.阿普拉肽,一种新型每周一次的胰高血糖素样肽-2 类似物,可改善短肠综合征患者的肠道液体和能量吸收:一项开放标签的 1 期和 2 期代谢平衡试验。
JPEN J Parenter Enteral Nutr. 2022 Sep;46(7):1639-1649. doi: 10.1002/jpen.2362. Epub 2022 Mar 28.
6
Efficacy of Teduglutide for Parenteral Support Reduction in Patients with Short Bowel Syndrome: A Systematic Review and Meta-Analysis.特杜格鲁肽减少短肠综合征患者肠外支持的疗效:系统评价和荟萃分析。
Nutrients. 2022 Feb 14;14(4):796. doi: 10.3390/nu14040796.
7
Dietary carbohydrate modifies the density of L cells in the chicken ileum.饮食碳水化合物可改变鸡回肠 L 细胞的密度。
J Vet Med Sci. 2022 Mar 1;84(2):265-274. doi: 10.1292/jvms.21-0572. Epub 2021 Dec 29.
8
Teduglutide in short bowel syndrome patients: A way back to normal life?特迪格鲁肽在短肠综合征患者中的应用:回归正常生活的途径?
JPEN J Parenter Enteral Nutr. 2022 Feb;46(2):300-309. doi: 10.1002/jpen.2272. Epub 2021 Oct 21.
9
Apraglutide, a novel glucagon-like peptide-2 analog, improves fluid absorption in patients with short bowel syndrome intestinal failure: Findings from a placebo-controlled, randomized phase 2 trial.阿普拉肽,一种新型胰高血糖素样肽-2 类似物,可改善短肠综合征肠衰竭患者的液体吸收:来自安慰剂对照、随机 2 期试验的结果。
JPEN J Parenter Enteral Nutr. 2022 May;46(4):896-904. doi: 10.1002/jpen.2223. Epub 2021 Sep 7.
10
MECHANISMS IN ENDOCRINOLOGY: The gut-brain axis: regulating energy balance independent of food intake.内分泌学机制:肠道-脑轴:调节能量平衡而不依赖于食物摄入。
Eur J Endocrinol. 2021 Aug 3;185(3):R75-R91. doi: 10.1530/EJE-21-0277.